Background Immune thrombocytopenia is a rare autoimmune disorder with associated
bleeding risk and fatigue. Recommended first-line treatment for immune thrombocytopenia …

Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized
by isolated thrombocytopenia caused by increased platelet destruction and impaired platelet …

Key Clinical Points Immune Thrombocytopenia Immune thrombocytopenia (ITP) is
diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom …

Immune thrombocytopenia (ITP) results from platelet destruction and production
suppression. Eltrombopag belongs to a new class of thrombopoietin-mimetic drugs that …

Refractory disease occurs in 25% or more of adults with idiopathic (immune)
thrombocytopenic purpura (ITP). Therapy to elevate the platelet count may be required in a …

Immune thrombocytopenia (ITP), previously called idiopathic thrombocytopenia purpura, is
an autoimmune disorder characterized by a severe reduction in peripheral blood platelet …

Immune thrombocytopenia (ITP) comprises a syndrome of diverse disorders that have in
common immune‐mediated thrombocytopenia, but that differ with respect to pathogenesis …

Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from
antibody-mediated destruction of platelets and impaired megakaryocyte platelet production …

Severe immune thrombocytopenia purpura (ITP) presents a clinical challenge. Second‐line
treatment options are variable without a precise protocol. We present 46 severe ITP patients …

Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders
characterized by autoimmune-mediated platelet destruction and impairment of …